VRTX Days sales outstanding
Days sales outstanding at Vertex Pharmaceuticals rose to 62.4 days in fiscal 2025, the highest in the 5 years reported, from 53.3 days in 2024.
Year-end receivables divided by total revenue, times 365. Both inputs as filed.
SOURCE: us-gaap:AccountsReceivableNetCurrent + us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · EDGAR CompanyFacts · CIK 875320 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Receivables | Revenue | DSO |
|---|---|---|---|
| FY2025 | $2.1B | $12.0B | 62.4 days |
| FY2024 | $1.6B | $11.0B | 53.3 days |
| FY2023 | $1.6B | $9.9B | 57.8 days |
| FY2022 | $1.4B | $8.9B | 58.9 days |
| FY2021 | $1.1B | $7.6B | 54.8 days |
More SAME DATA, OTHER VIEWS
Days sales outstanding across coverage → · VRTX company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Return on equity
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.